Society guideline links: Chemotherapy-induced nausea and vomiting

Introduction —

This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.

The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.

Links to related guidelines are provided separately. (See "Society guideline links: Nausea and vomiting".)

International

●Multinational Association of Supportive Care in Cancer (MASCC)/European Society for Medical Oncology (ESMO): Antiemetic guidelines, 2023 update (published 2024)

●MASCC and ESMO: Guideline for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting, 2023 update (published 2024)

●MASCC: Guideline on antiemetics in advanced cancer, update (2021)

Canada

●Pediatric Oncology Group of Ontario (POGO): Clinical practice guidelines on chemotherapy-induced nausea and vomiting

•Clinical practice guideline for treatment of breakthrough and prevention of refractory chemotherapy-induced nausea and vomiting in pediatric cancer patients, update (2023)

•A clinical practice guideline for prevention of acute and delayed chemotherapy-induced nausea and vomiting in pediatric cancer patients (2022)

•Clinical practice guideline for prevention and treatment of anticipatory chemotherapy-induced nausea and vomiting in pediatric cancer patients and hematopoietic stem cell recipients, update (2021)

•A clinical practice guideline on classification of the acute emetogenicity of chemotherapy in pediatric patients (2019)

●Cancer Care Ontario (CCO): Antiemetic recommendations for chemotherapy-induced nausea and vomiting – A clinical practice guideline (2019)